These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...

Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. | AstraZeneca has ...

Last week, the immuno-oncology specialist revealed that part of the new setup will include CDMO services, as it will produce ...

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...